Summary
Shares of Zealand Pharma plunged roughly 26% on the announcement of full Phase III results for survodutide. While the study met primary efficacy endpoints — including substantial weight loss over 76 weeks and marked reductions in visceral and liver fat — a 19% discontinuation rate attributed to gastrointestinal side effects, compared with 2.9% on placebo, appears to have driven investor concern about tolerability.
Trial findings and presentation
The Phase III dataset was released at the American Diabetes Association Scientific Sessions and published simultaneously in the New England Journal of Medicine. According to the published results, survodutide delivered up to 16.6% weight loss over the 76-week treatment period. In body-composition analyses, the drug reduced visceral fat by up to 34% and liver fat by as much as 63%. Changes attributed to lean mass did not exceed 10.8% of the overall body-composition shift.
Despite those efficacy measures, the trial recorded a substantially higher rate of patient discontinuation due to gastrointestinal adverse events - 19% - versus 2.9% in the placebo arm. That contrast in tolerability figures was singled out as a primary factor in the market reaction.
MASLD results
In a separate MASLD trial included in the dataset, 84.2% of participants achieved at least a 30% reduction in liver fat, compared with 24.3% for placebo. The MASLD finding underscores the agent's effects on liver fat, even as tolerability concerns remain prominent.
Market implications
Investors reacted sharply to the tolerability profile, weighing the observed efficacy against the rate of discontinuations. Analysts and market participants have noted the comparison to competitors such as Wegovy and Zepbound, which the data release referenced as having established safety profiles; the higher dropout rate for survodutide was interpreted as a negative relative signal on tolerability.
What remains clear
The Phase III program produced meaningful efficacy signals on weight loss and reductions in visceral and liver fat, and the MASLD study reported a high responder rate for liver-fat reduction. At the same time, the 19% discontinuation rate for gastrointestinal side effects, contrasted with 2.9% on placebo, has become the focal point for market concern and explains the pronounced share-price decline.